UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 108

Sortiert nach

Loss of Mitochondrial Pyruvate Carrier 2 in the Liver Leads to Defects in Gluconeogenesis and Compensation via Pyruvate-Alanine Cycling

Cell metabolism, 2015-10, Vol.22 (4), p.682-694

2015

Volltextzugriff (PDF)

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

Journal of hepatology, 2020-04, Vol.72 (4), p.613-626

2020

Volltextzugriff (PDF)

MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis

Expert opinion on investigational drugs, 2018-07, Vol.27 (7), p.631-636

2018

Volltextzugriff (PDF)

The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease

Molecular metabolism (Germany), 2022-01, Vol.55, p.101409-101409, Article 101409

2022

Volltextzugriff (PDF)

Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease

Science translational medicine, 2016-12, Vol.8 (368), p.368ra174

2016

Volltextzugriff (PDF)

Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier

Proceedings of the National Academy of Sciences - PNAS, 2013-04, Vol.110 (14), p.5422-5427

2013

Volltextzugriff (PDF)

Mitochondrial Pyruvate Carrier 2 Hypomorphism in Mice Leads to Defects in Glucose-Stimulated Insulin Secretion

Cell reports (Cambridge), 2014-06, Vol.7 (6), p.2042-2053

2014

Volltextzugriff (PDF)

Metabolic Mechanisms Connecting Alzheimer's and Parkinson's Diseases: Potential Avenues for Novel Therapeutic Approaches

Frontiers in molecular biosciences, 2022-06, Vol.9, p.929328-929328

2022

Volltextzugriff (PDF)

Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism

Molecular metabolism (Germany), 2023-04, Vol.70, p.101694-101694, Article 101694

2023

Volltextzugriff (PDF)

The Site of Action of Oxazolidinone Antibiotics in Living Bacteria and in Human Mitochondria

Molecular cell, 2007-05, Vol.26 (3), p.393-402

2007

Volltextzugriff (PDF)

Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials

Journal of hepatology, 2020-12, Vol.73 (6), p.1322-1332

2020

Volltextzugriff (PDF)

Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe

American journal of physiology: endocrinology and metabolism, 2004-02, Vol.286 (2), p.E252-E260

2004

Volltextzugriff (PDF)

Novel insulin sensitizer modulates nutrient sensing pathways and maintains β-cell phenotype in human islets

PloS one, 2013-05, Vol.8 (5), p.e62012-e62012

2013

Volltextzugriff (PDF)

The TZD insulin sensitizer clue provides a new route into diabetes drug discovery

Expert opinion on drug discovery, 2015-12, Vol.10 (12), p.1259-1270

Colca, Jerry R.

2015

Volltextzugriff (PDF)

Re-routing Metabolism by the Mitochondrial Pyruvate Carrier Inhibitor MSDC-0160 Attenuates Neurodegeneration in a Rat Model of Parkinson’s Disease

Molecular neurobiology, 2022-10, Vol.59 (10), p.6170-6182

2022

Volltextzugriff (PDF)

Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis

Hepatology (Baltimore, Md.), 2017-05, Vol.65 (5), p.1543-1556

2017

Volltextzugriff (PDF)

Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide

The Journal of biological chemistry, 2021-01, Vol.296, p.100807-100807, Article 100807

2021

Volltextzugriff (PDF)

Insulin sensitizers in 2023: lessons learned and new avenues for investigation

Expert opinion on investigational drugs, 2023-09, Vol.32 (9), p.803-811

2023

Volltextzugriff (PDF)

Discontinued drug therapies to treat diabetes in 2014

Expert opinion on investigational drugs, 2015-09, Vol.24 (9), p.1241-1245

Colca, Jerry R

2015

Volltextzugriff (PDF)

An Insulin‐Sensitizing Thiazolidinedione, Which Minimally Activates PPARγ, Does Not Cause Bone Loss

Journal of bone and mineral research, 2015-03, Vol.30 (3), p.481-488

2015

Volltextzugriff (PDF)

Cross-linking in the Living Cell Locates the Site of Action of Oxazolidinone Antibiotics

The Journal of biological chemistry, 2003-06, Vol.278 (24), p.21972-21979

2003

Volltextzugriff (PDF)

1786-P: The New Insulin Sensitizer MSDC-0602K Synergizes with the GLP-1 Receptor Agonist Liraglutide

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

768-P: MSDC-0602 Is a Direct Mitochondrial Pyruvate Carrier Inhibitor That Modulates Central Carbon Metabolism in Mice and Humans

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

213-LB: Mechanisms of Metabolic Cross Talk between Mitochondrial Pyruvate Carrier Inhibition and Branched-Chain Amino Acid Catabolism in Hepatocytes

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Inhibiting the mitochondrial pyruvate carrier does not ameliorate synucleinopathy in the absence of inflammation or metabolic deficits

Free Neuropathology, 2020-01, Vol.1, p.33-33

2020

Volltextzugriff (PDF)

1 – 25 von 108

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)
Mit Volltextzugriff
(87)

Publikationsform

Sprache

Englisch
(108)
Japanisch
(17)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Loss of Mitochondrial Pyruvate Carrier 2 in the Liver Leads to Defects in Gluconeogenesis and Compensation via Pyruvate-Alanine Cycling

Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study

MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis

The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease

Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease

Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier

Mitochondrial Pyruvate Carrier 2 Hypomorphism in Mice Leads to Defects in Glucose-Stimulated Insulin Secretion

Metabolic Mechanisms Connecting Alzheimer's and Parkinson's Diseases: Potential Avenues for Novel Therapeutic Approaches

Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism

The Site of Action of Oxazolidinone Antibiotics in Living Bacteria and in Human Mitochondria

Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials

Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe

Novel insulin sensitizer modulates nutrient sensing pathways and maintains β-cell phenotype in human islets

The TZD insulin sensitizer clue provides a new route into diabetes drug discovery

Re-routing Metabolism by the Mitochondrial Pyruvate Carrier Inhibitor MSDC-0160 Attenuates Neurodegeneration in a Rat Model of Parkinson’s Disease

Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis

Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide

Insulin sensitizers in 2023: lessons learned and new avenues for investigation

Discontinued drug therapies to treat diabetes in 2014

An Insulin‐Sensitizing Thiazolidinedione, Which Minimally Activates PPARγ, Does Not Cause Bone Loss

Cross-linking in the Living Cell Locates the Site of Action of Oxazolidinone Antibiotics

1786-P: The New Insulin Sensitizer MSDC-0602K Synergizes with the GLP-1 Receptor Agonist Liraglutide

768-P: MSDC-0602 Is a Direct Mitochondrial Pyruvate Carrier Inhibitor That Modulates Central Carbon Metabolism in Mice and Humans

213-LB: Mechanisms of Metabolic Cross Talk between Mitochondrial Pyruvate Carrier Inhibition and Branched-Chain Amino Acid Catabolism in Hepatocytes

Inhibiting the mitochondrial pyruvate carrier does not ameliorate synucleinopathy in the absence of inflammation or metabolic deficits

Suchergebnisse filtern